AstraZeneca Pharmaceuticals, LP – FDA 483, Jun 26, 2026

An FDA inspection of AstraZeneca Pharmaceuticals, LP in Newark, DE, identified critical deficiencies in equipment cleaning validation and procedures. Investigators found visible drug product residues on shared manufacturing equipment that was previously documented as cleaned. These findings indicate a significant risk of cross-contamination and a failure to maintain adequate cleanliness standards in drug production.